CLINICAL TRIALS PROFILE FOR DIPYRIDAMOLE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for dipyridamole
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT02273518 ↗ | Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers | Completed | Boehringer Ingelheim | Phase 1 | 2001-04-01 | Comparative pharmacokinetics of dipyridamole in two new formulations of Asasantin ER compared to the present commercial formulation |
| New Formulation | NCT02273531 ↗ | Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers | Completed | Boehringer Ingelheim | Phase 1 | 2004-01-01 | Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®) |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for dipyridamole
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000463 ↗ | Post Coronary Artery Bypass Graft (CABG) Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1987-04-01 | To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously. |
| NCT00000496 ↗ | Platelet Drug Trial in Coronary Disease Progression | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1979-12-01 | To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in reducing the angiographic progression of coronary artery disease over a five-year period and to test the predictive value of the platelet survival half-life in identifying patients with more rapid progression of coronary disease and development of its complications. |
| NCT00000510 ↗ | Platelet-Inhibitor Drug Trial in Coronary Angioplasty | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1983-09-01 | To determine the effectiveness of dipyridamole and aspirin in prevention of restenosis of the dilated lesion in patients who had undergone percutaneous transluminal coronary angioplasty (PTCA). Secondary aims were to determine the effectiveness of platelet inhibitor therapy in reducing the incidence of coronary events and the severity and incidence of angina. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dipyridamole
Condition Name
Clinical Trial Locations for dipyridamole
Trials by Country
Clinical Trial Progress for dipyridamole
Clinical Trial Phase
Clinical Trial Sponsors for dipyridamole
Sponsor Name
